Close Menu
    Facebook X (Twitter) Instagram
    Latest
    • A new malpractice being observed: Reviewers asking their own papers to cite
    • 100% APC Waiver for Authors from “Group A” Category Countries Indicated by Research4Life
    • Retraction Notice: Pharmacological Actions of Impatiens
    • DOI Allocated and Activated for 281 Articles and Abstracts Published in the period of 2014-2017
    • IGJPS, 2021, Vol 11, Issue 3
    • IGJPS, 2021, Vol 11, Issue 2
    • IGJPS, 2021, Vol 11, Issue 1
    • Table of Contents, Vol 10, Issue 4
    INDO GLOBAL JOURNAL OF PHARMACEUTICAL SCIENCESINDO GLOBAL JOURNAL OF PHARMACEUTICAL SCIENCES
    • Home
    • About Us
    • Issues
      • IGJPS 2022 and Onwards
      • IGJPS, 2021, Vol 11, Issue 3
      • IGJPS, 2021, Vol 11, Issue 2
      • IGJPS, 2021, Vol 11, Issue 1
      • IGJPS, 2020, Vol 10, Issue 4
      • IGJPS, 2020, Vol 10, Issue 3
      • IGJPS, 2020, Vol 10, Issue 2
      • IGJPS, 2020, Vol 10, Issue 1
      • IGJPS, 2019, Vol 9, Issue 2 (Suppl.)
      • IGJPS, 2019, Vol 9, Issue 2
      • IGJPS, 2019, Vol 9, Issue 1
      • IGJPS, 2018, Vol 8, Issue 3
      • IGJPS, 2018, Vol 8, Issue 2
      • IGJPS, 2018, Vol 8, Issue 1
      • IGJPS, 2017, Vol 7, Issue 2
      • IGJPS, 2017, Vol 7, Issue 1
      • IGJPS, 2016, Vol 6, Issue 2
      • IGJPS, 2016, Vol 6, Issue 1
      • IGJPS, 2015, Vol 5, Issue 3
      • IGJPS, 2015, Vol 5, Issue 2
      • IGJPS, 2015, Vol 5, Issue 1
      • IGJPS, 2014, Vol 4, Issue 3
      • IGJPS, 2014, Vol 4, Issue 2
      • IGJPS, 2014, Vol4, Issue 1
      • IGJPS, 2013, Vol 3, Issue 3
      • IGJPS,2013, Vol 3, Issue 2
      • IGJPS, 2013, Vol 3, Issue 1
      • IGJPS, 2012, Vol 2, Issue 4
      • IGJPS, 2012, Vol 2, Issue 3
      • IGJPS, 2012, Vol 2, Issue 2
      • IGJPS, 2012, Vol 2, Issue 1
      • IGJPS, 2011, Vol 1, Issue 4
      • IGJPS, 2011, Vol 1, Issue 3
      • IGJPS, 2011, Vol 1, Issue 2
      • IGJPS, 2011, Vol 1, Issue 1
    • Editorial Board
    • Guidelines For Authors
    • Indexed
    • Manuscript Submission
    • Contact Us
    INDO GLOBAL JOURNAL OF PHARMACEUTICAL SCIENCESINDO GLOBAL JOURNAL OF PHARMACEUTICAL SCIENCES
    You are at:Home»News»FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri

    FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri

    0
    By Rajeev Singla on January 21, 2012 News

    Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn’s disease (CD).

    The Stratify JCV Antibody ELISA test, when used with other clinical data from the patient, can help health care providers determine the risk for developing PML in MS and CD patients.

    The John Cunningham virus (JCV) is a common virus that many people have been exposed to at some point in their lives, and is generally harmless. However, people with weakened immune systems, such as patients using immunomodulatory therapies like Tysabri, have an increased chance of developing PML from JCV. PML usually causes death or severe disability.

    Currently, there is no treatment, prevention, or cure for PML, and no certain way to predict who will develop it. This test in conjunction with other factors listed below will allow the physicians and patients to carefully assess the risks and benefits of continuing Tysabri treatment depending on the complete clinical information for the particular patient.  The following risk factors have been identified that increase the chance of Tysabri-treated patients developing PML:

    • the presence of anti-JCV antibodies, which reflects prior exposure to JCV
    • treatment with Tysabri for a significant period of time (longer than 2 years)
    • treatment with certain medicines that can weaken a patient’s immune system (immunosuppressants such as mitoxantrone, azathioprine, methotrexate, cyclophosphamide, and mycophenolate mofetil) before receiving Tysabri.

    The risk of getting PML is greatest (about 11/1000 patients treated) if the patient has all three of these risk factors.

    “PML is a fatal infection reported in patients undergoing immunomodulatory therapy,” said Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostics in FDA’s Center for Devices and Radiological Health. “This test gives doctors an additional means to determine if MS or CD patients undergoing Tysabri therapy are at increased risk for developing PML.”

    The FDA reviewed data for the Stratify JCV Antibody ELISA test through the de novo reclassification process, a regulatory pathway for low- to moderate-risk medical devices that are novel and not comparable to an already legally marketed device.

    In a separate action, the FDA also announced updates to the drug label for Tysabri. The change includes information that testing positive for anti-JCV antibodies is a recently identified risk factor for developing PML in patients treated with Tysabri for MS or CD.

    The Stratify JCV Antibody ELISA test should not be used on its own as a basis for determining the risk for developing PML in patients on immunomodulatory therapy or for making clinical decisions. The test cannot be used to diagnose PML.

    The test is for professional use and by prescription only and is to be performed only at Focus Diagnostics’ Reference Laboratory. The test is not intended for blood donor screening. The performance of this test has not been established for use in neonates, pediatric patients or any other immunocompromised patient populations.

    The Stratify JCV Antibody ELISA test is manufactured by Focus Diagnostics of Cypress, Calif.

    Tysabri is co-marketed by Cambridge, Mass.-based Biogen Idec and Elan Pharmaceuticals whose U.S. operations are based in South San Francisco, Calif.

     

    Source- U S FDA

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    A new malpractice being observed: Reviewers asking their own papers to cite

    100% APC Waiver for Authors from “Group A” Category Countries Indicated by Research4Life

    Retraction Notice: Pharmacological Actions of Impatiens

    Comments are closed.

    Latest News
    A new malpractice being observed: Reviewers asking their own papers to cite
    ...
    100% APC Waiver for Authors from “Group A” Category Countries Indicated by Research4Life
    ...
    Retraction Notice: Pharmacological Actions of Impatiens
    ...
    DOI Allocated and Activated for 281 Articles and Abstracts Published in the period of 2014-2017
    ...
    Top Peer Reviewer as New Associate Editor: Dr. Ghulam Md. Ashraf, King Abdulaziz University, Jeddah, Saudi Arabia
    ...
    Highly Cited Articles

    Microencapsulation–A Novel Approach in Drug Delivery: A Review

    Review on the pharmacognostical & pharmacological characterization of Apium graveolens Linn


    Medicinal Plants of Rural India: A Review of Use by Indian Folks


    Self Emulsifying Drug Delivery System: A Tool in Solubility Enhancement of Poorly Soluble Drugs


    Antioxidant and antimicrobial activities of Cocos nucifera Linn.(Arecaceae) endocarp extracts

    Impotant Links
    • About Us
    • Call For Papers
    • Contact Us
    • Editorial Board
    • For Reviewers
    • Guidelines For Authors
    • Home Page
    • Indexed
    • Issues
    • Manuscript Submission
    • Checkout
    • Transaction Results
    • Your Account
    Sponsored
    Copyright © 2011 iGlobal Research & Publishing Foundation
    Powered By :- Ganga Graphix.

    Type above and press Enter to search. Press Esc to cancel.